Four IPOs each raised at least $75 million this week as the Fall IPO market continued to hum along, while one company ...

Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest ...

Biotech IPO activity in the US has spiked for the second time this year, following an initial boost in Q1 2024. Largely ...

Three U.S. healthcare startups priced their initial public offerings (IPO) on Thursday, including Upstream Bio which raised ...

RNA biotech CAMP4 Therapeutics has marked out plans for a $67 million IPO, with inflammation-focused Upstream Bio pegging its ...

Shares of Upstream Bio opened 26.5% above the initial public offering price in their Nasdaq debut on Friday, valuing the drug ...

(Reuters) - CAMP4 Therapeutics, a biopharmaceutical company backed by healthcare giant Kaiser Permanente, said on Monday it ...

A new report identifies six Massachusetts startup "unicorns" as life science companies most likely to hold initial public ...

The US IPO market is seeing renewed momentum as the 2024 presidential election approaches, with investors and analysts eyeing ...

LATEST IPOS AND DIRECT LISTINGS ... Camp4 is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with ...

Candid Therapeutics recorded San Diego’s largest venture capital deal during the third quarter. It was also the fourth largest deal in California.

Two biotechs set out for the public markets this week, with Upstream Bio raising $255 million for its inflammatory disease ...